Revvity, Inc. (NYSE: RVTY), announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom.

Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced updates on its oncology assay portfolio and regulatory milestones, ahead of its presence at the AMP 2024 meeting.

Oxford Nanopore, announced a landmark strategic partnership with the UK Government. This partnership brings together the UK’s world-class scientific organisations Genomics England, UK Biobank and NHS England, alongside Oxford Nanopore.

Alfa Chemistry is delighted to announce the launch of its much-anticipated Scholarship Program 2024, aimed at supporting and empowering chemistry-related college students.

Thermo Fisher Scientific has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with Servier Pharmaceuticals.